Published in Blood on June 30, 2008
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
Toll-like receptors--sentries in the B-cell response. Immunology (2009) 1.52
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol (2009) 1.50
Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med (2010) 1.41
Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology (2009) 1.23
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother (2010) 1.21
The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum Genet (2011) 1.17
B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J Immunol (2009) 1.14
Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. BMC Immunol (2012) 1.01
Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood (2012) 1.00
Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. J Immunol (2011) 0.99
Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation. J Immunol (2009) 0.95
IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner. J Biol Chem (2011) 0.92
Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood (2009) 0.92
B-lymphocyte lineage cells and the respiratory system. J Allergy Clin Immunol (2013) 0.89
An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS One (2012) 0.89
The Role of PPARs in Placental Immunology: A Systematic Review of the Literature. PPAR Res (2013) 0.84
Macropinocytosis is responsible for the uptake of pathogenic and non-pathogenic mycobacteria by B lymphocytes (Raji cells). BMC Microbiol (2012) 0.83
Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. J Clin Invest (2014) 0.83
Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol (2014) 0.83
TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism. Cell Death Dis (2012) 0.82
Characterization of the Toll-like receptor expression profile in human multiple myeloma cells. PLoS One (2013) 0.81
Innate immunity and hepatitis C virus infection: a microarray's view. Infect Agent Cancer (2012) 0.80
Distinct Differentiation Programs Triggered by IL-6 and LPS in Teleost IgM(+) B Cells in The Absence of Germinal Centers. Sci Rep (2016) 0.78
Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas. Cell Commun Signal (2012) 0.77
Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. Int J Radiat Oncol Biol Phys (2017) 0.76
Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion. Leuk Lymphoma (2011) 0.76
Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells. Blood Cancer J (2013) 0.76
Dysregulated B-cell TLR2 expression and elevated regulatory B-cell frequency precede the diagnosis of AIDS-related non-Hodgkin lymphoma. AIDS (2015) 0.75
Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application. J Transl Med (2017) 0.75
Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells. PLoS One (2017) 0.75
Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis. PLoS One (2014) 0.75
Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. PLoS One (2016) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
TLR signaling. Cell Death Differ (2006) 9.24
The molecular classification of multiple myeloma. Blood (2006) 8.77
Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science (2006) 6.47
Control of B-cell responses by Toll-like receptors. Nature (2005) 6.44
Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol (2006) 6.00
Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol (2004) 5.24
Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol (2002) 5.08
Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med (2003) 4.96
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity (2003) 4.93
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 4.32
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 4.23
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06
A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood (2003) 3.77
Endogenous ligands of Toll-like receptors. J Leukoc Biol (2004) 3.53
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood (2004) 3.17
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood (2006) 3.04
FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol (2007) 3.04
Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol (2006) 2.94
Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev (2004) 2.75
Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res (2006) 2.61
The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood (2003) 2.57
Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev (2005) 2.47
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood (2006) 2.36
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol (2005) 2.31
Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev (2007) 2.22
TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology (2008) 2.19
TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol (2007) 2.13
CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol (2004) 2.08
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene (2008) 1.94
The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia (2006) 1.92
B cell intrinsic TLR signals amplify but are not required for humoral immunity. J Exp Med (2007) 1.89
Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One (2007) 1.82
Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biol (2004) 1.75
Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia (2006) 1.67
Immunology: Toll-like receptors and antibody responses. Nature (2006) 1.64
Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia (2006) 1.63
T-independent activation-induced cytidine deaminase expression, class-switch recombination, and antibody production by immature/transitional 1 B cells. J Immunol (2007) 1.60
Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing. J Exp Med (1997) 1.59
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood (2000) 1.51
Class switch recombination and somatic hypermutation in early mouse B cells are mediated by B cell and Toll-like receptors. Immunity (2007) 1.50
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res (2005) 1.49
Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev (2007) 1.47
TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol (2007) 1.45
Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood (2006) 1.39
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol (2001) 1.30
A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. Immunology (2006) 1.27
Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun (2005) 1.26
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol (2008) 1.25
MyD88 is required for the formation of long-term humoral immunity to virus infection. J Immunol (2007) 1.24
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia (2006) 1.17
TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur J Immunol (2008) 1.15
Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J Immunol (2007) 1.15
Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol (2004) 1.13
Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol (2000) 1.09
Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia (2006) 1.07
Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica (2006) 1.07
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol (2002) 1.06
Staphylococcus aureus protein A triggers T cell-independent B cell proliferation by sensitizing B cells for TLR2 ligands. J Immunol (2007) 1.02
Antibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II fcgamma receptor (CD32). Virology (2000) 1.02
Toll-like receptor 2-mediated human B cell differentiation. Clin Immunol (2006) 0.99
Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J Leukoc Biol (2007) 0.98
Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res (2005) 0.97
Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res (2007) 0.95
HMGB1 expression and release by bone cells. J Cell Physiol (2006) 0.95
Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol (2006) 0.91
Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol Ther (2007) 0.88
Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma (2005) 0.87
Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol (1995) 0.84
Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol (2006) 0.83
Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells. Leuk Lymphoma (1999) 0.76
Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle. Blood (1994) 0.76
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood (2002) 2.38
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res (2007) 2.37
Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int (2010) 2.28
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica (2006) 2.12
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood (2002) 1.87
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica (2010) 1.80
Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood (2002) 1.42
In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci U S A (2011) 1.36
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood (2005) 1.35
ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood (2011) 1.35
Hsp70: anti-apoptotic and tumorigenic protein. Methods Mol Biol (2011) 1.29
CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica (2005) 1.16
Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol (2013) 1.15
Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene (2005) 1.15
The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol (2004) 1.11
Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol (2006) 1.10
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood (2003) 1.09
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood (2005) 1.09
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res (2012) 1.08
Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency. J Allergy Clin Immunol (2013) 1.08
Phenotypic characterization of the human myeloma cell growth fraction. Blood (2005) 1.04
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood (2006) 1.03
Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. Biochem Biophys Res Commun (2011) 1.02
New insights in myeloma-induced osteolysis. Leuk Lymphoma (2003) 1.01
Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat (2007) 1.00
Endogenous association of Bim BH3-only protein with Mcl-1, Bcl-xL and Bcl-2 on mitochondria in human B cells. Eur J Immunol (2005) 1.00
B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun (2011) 0.99
Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood (2004) 0.98
IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol (2008) 0.98
The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol (2011) 0.97
14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol (2003) 0.97
Impact of XIAP protein levels on the survival of myeloma cells. Haematologica (2008) 0.96
CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res (2007) 0.95
CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol (2006) 0.95
Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. Biochem Biophys Res Commun (2007) 0.95
The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma. Br J Haematol (2009) 0.95
Staphylococcus aureus-induced plasmacytoid dendritic cell activation is based on an IgG-mediated memory response. J Immunol (2008) 0.95
TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol (2009) 0.93
Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res (2005) 0.90
A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev (2003) 0.90
Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin Cancer Res (2007) 0.90
Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program (2003) 0.89
A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness. J Biol Chem (2010) 0.89
The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol (2004) 0.88
CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol (2002) 0.88
Pathogen-triggered activation of plasmacytoid dendritic cells induces IL-10-producing B cells in response to Staphylococcus aureus. J Immunol (2013) 0.87
Osteoclasts support the survival of human plasma cells in vitro. Int Immunol (2008) 0.87
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Res Treat (2008) 0.87
Induction of type I IFN is a physiological immune reaction to apoptotic cell-derived membrane microparticles. J Immunol (2012) 0.87
Rapid brain death caused by a cerebellar abscess with Fusobacterium nucleatum in a young man with drug abuse: a case report. BMC Res Notes (2014) 0.86
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leuk Lymphoma (2014) 0.86
The biofilm mode of life boosts the anti-inflammatory properties of Lactobacillus. Cell Microbiol (2014) 0.86
Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. Eur Cytokine Netw (2007) 0.85
Serum vitamin D concentration and short-term mortality among geriatric inpatients in acute care settings. Adv Ther (2010) 0.85
TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA. J Immunother (2009) 0.83
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis (2012) 0.83
Ca(2+) -related signaling events influence TLR9-induced IL-10 secretion in human B cells. Eur J Immunol (2014) 0.83
Plasma beta-2 microglobulin as a marker of frailty in older adults: a pilot study. J Gerontol A Biol Sci Med Sci (2011) 0.83
Bifunctional oligodeoxynucleotide/antagomiR constructs: evaluation of a new tool for microRNA silencing. Nucleic Acid Ther (2013) 0.82
[Survivin in cancerology : molecular aspects and therapeutic applications]. Med Sci (Paris) (2008) 0.81
Mcl-1(128-350) fragment induces apoptosis through direct interaction with Bax. FEBS Lett (2009) 0.81
Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. Blood (2002) 0.81
Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. Bone (2003) 0.81
Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol (2009) 0.80
Cohen syndrome is associated with major glycosylation defects. Hum Mol Genet (2013) 0.80
IRAK4 turns IL-10+ phospho-FOXO+ monocytes into pro-inflammatory cells by suppression of protein kinase B. Eur J Immunol (2013) 0.80
Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Eur J Cell Biol (2010) 0.79
Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Cancer Biol Ther (2015) 0.79
Plasmacytoid dendritic cells control B cell-derived IL-10 production. Autoimmunity (2012) 0.79
Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment? Cancer Res (2004) 0.79
Heterozygous carriage of a dysfunctional Toll-like receptor 9 allele affects CpG oligonucleotide responses in B cells. J Biol Chem (2012) 0.79
Functional variation reflects intra-strain diversity of Staphylococcus aureus small colony variants in the host-pathogen interaction. Int J Med Microbiol (2013) 0.79
TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. Front Immunol (2011) 0.79
Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia. Support Care Cancer (2015) 0.79
A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms. Mol Cancer Res (2012) 0.78
Apoptotic-cell-derived membrane vesicles induce an alternative maturation of human dendritic cells which is disturbed in SLE. J Autoimmun (2012) 0.78
Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse. Biochem Biophys Res Commun (2004) 0.78
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines. Cytometry A (2015) 0.77
PDC expressing CD36, CD61 and IL-10 may contribute to propagation of immune tolerance. Autoimmunity (2009) 0.76
Correction: The νSaα Specific Lipoprotein Like Cluster (lpl) of S. aureus USA300 Contributes to Immune Stimulation and Invasion in Human Cells. PLoS Pathog (2015) 0.75
Phosphorothioate-modified CpG oligodeoxynucleotides mimic autoantigens and reveal a potential role for Toll-like receptor 9 in receptor revision. Immunology (2013) 0.75